Why AngioDynamics Crashed Today

AngioDynamics reported fiscal Q1 2027 sales of $80.9 million, up 6.9% year over year, and a pro forma loss of $0.04 per share versus analysts’ expected $0.11 loss; its GAAP loss was $0.17 per share, down from $0.24 a year earlier. Shares fell 20.7% by 10:20 a.m. ET despite the forecast beat. The company appointed Eric Honroth as CEO and forecast fiscal 2027 sales of $336 million-$341 million and pro forma losses of $0.24-$0.29 per share; analysts do not expect profitability before 2029.

Analysis

ANGO: earnings quality, not the headline beat, is the issue. The gap between adjusted and GAAP results makes reconciliation—not the beat—the key diligence item: separate recurring cash costs from noncash or one-off charges before inferring the underlying burn rate. The reported cash balance and absence of debt reduce near-term financing pressure, but do not establish runway without operating cash-flow data. Modest growth alongside continued losses leaves little evidence yet that scale is producing operating leverage.

The CEO change creates an execution catalyst, not an immediate fundamental reset. Over the next 1–3 months, watch for revised guidance, restructuring or investment priorities, and evidence that commercial execution is improving. Over 6–18 months, durable organic growth, margins, and cash conversion matter more than adjusted EPS. Compare operating trends with diversified medtech names such as Boston Scientific (BSX), Medtronic (MDT), and Merit Medical (MMS), while recognizing these are imperfect, broader businesses rather than clean comps. Honroth’s prior role at Getinge does not by itself imply a material benefit or risk to GETI.B.

The bearish case is plausible, but a sharp post-report decline may already price in disappointment; avoid chasing a short before seeing cash-flow and guidance detail. Thesis weakens if ANGO delivers sustained growth with improving gross/operating margins and cash conversion, or if GAAP-adjustment items prove largely nonrecurring. It strengthens on guidance cuts, persistent cash deterioration, or another widening gap between adjusted and GAAP performance.

Key Decisions for Investors

• Do not initiate a momentum short after the sharp selloff. Reassess after the next guidance or operating update; consider a short only if growth or cash conversion deteriorates and the price stabilizes enough to define risk.
• Put ANGO on a watchlist rather than treating the adjusted-EPS beat as a long signal. Verify the GAAP-to-adjusted reconciliation, quarterly operating cash flow, cash trend, and any changes to full-year guidance.
• Use BSX, MDT, and MMS as broad medtech performance benchmarks, not as precise hedges; their diversified earnings drivers may not offset ANGO-specific execution risk.
• Falsification trigger: sustained improvement in organic growth, margins, and cash conversion would challenge the turnaround skepticism; a guidance reduction or accelerating cash use would reinforce it.